Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Parallel Design, Active-controlled Phase 3 Study to Determine Efficacy and Safety Following Administration of SMO1 in Patients With Retinal Vein Occlusive Macular Edema

NCT07708142 is registered in ClinicalTrials.gov with SANGMYUNG innovation as lead sponsor.

NCT NCT07708142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07708142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Parallel Design, Active-controlled Phase 3 Study to Determine Efficacy and Safety Following Administration of SMO1 in Patients With Retinal Vein Occlusive Macular Edema
Lead sponsor
SANGMYUNG innovation
Phase
Phase 3
Overall status
Recruiting
Start date
January 29, 2026
Completion date
January 31, 2028
Enrollment
312 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal vein occlusion with macular edema